Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia

Minimal or measurable residual disease (MRD) after therapy is the most important independent prognostic factor in acute myeloid leukemia. MRD measured by multiparametric flow cytometry and real-time quantitative polymerase chain reaction has been integrated into risk stratification and used to guide future treatment strategies. Recent technological advances have allowed the application of the novel molecular method, high-throughput sequencing, in MRD detection in clinical practice to improve sensitivity and specificity. Randomized studies are needed to address outstanding issues, including the optimal methods and timing of MRD testing and interlaboratory standardization to facilitate comparisons, to further improve MRD-directed interventions.

Source: Clinics in Laboratory Medicine - July 2, 2021 Category: Laboratory Medicine Authors: Xueyan Chen, Sindhu Cherian Source Type: research